Epileptic seizures as a sign of abstinence from chronic consumption of zolpidem

被引:9
作者
Barrero-Hernández, FJ
Ruiz-Veguilla, M
López-López, MI
Casado-Torres, A
机构
[1] Hosp Univ San Cecilio, Serv Neurol, Granada, Spain
[2] Hosp Univ San Cecilio, Serv Psiquiatria, Granada, Spain
关键词
abstinence syndrome; abuse; dependence; tolerance; tonic-clonic seizures; zolpidem;
D O I
10.33588/rn.3403.2001316
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Zolpidem is derived from imidazopiridine. In recent years it has been used as a 'non-benzodiazepine 'hypnotic. It is a short-acting inducer of sleep of similar efficacy to the benzodiazepines or zopiclone, but well tolerated and does not lead to drug-abuse, rebound effects or abstinence syndromes. In this clinical note we wish to show that in spite of the descriptions in the medical literature, complications may follow long-term use of zolpidem. Clinical case. We report the case of a 50 year old woman with no clinical history of interest apart from chronic insomnia and anxiety. She had been treated with zolpidem for the previous five years, at the usual dosage. However, since this seemed to be insufficient, the dose was progressively increased until in the months before she was seen by us she was taking a total of 450 mg per day in divided doses. She had drug tolerance, abuse and dependence. After a period of 12 hours without taking zolpidem she developed an abstinence syndrome, with generalized tonic-clonic seizures and a prolonged post-convulsion period which improved on symptomatic anticonvulsant treatment. Conclusions. In view of our case, and others described, we should be sceptical of the claim that zolpidem has no side-effects, since it may give rise to tolerance, abuse and an abstinence syndrome. We consider that its indiscriminate use should be modified. Patients should he carefully followed-up and medical prescription necessary to obtain zolpidem, as opposed to its current unrestricted availability.
引用
收藏
页码:253 / 256
页数:4
相关论文
共 30 条
[1]   Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography [J].
Abadie, P ;
Rioux, P ;
Scatton, B ;
Zarifian, E ;
Barre, L ;
Patat, A ;
Baron, JC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 295 (01) :35-44
[2]   General safety profile of zolpidem: Safety in elderly, overdose and rebound effects [J].
Allain, H ;
Monti, J .
EUROPEAN PSYCHIATRY, 1997, 12 :S21-S29
[3]   PSYCHOTIC REACTIONS TO ZOLPIDEM [J].
ANSSEAU, M ;
PITCHOT, W ;
HANSENNE, M ;
MORENO, AG .
LANCET, 1992, 339 (8796) :809-809
[4]  
BLOIS R, 1993, CLIN THER, V15, P797
[5]   Zolpidem dependence in a patient with former polysubstance abuse [J].
Bottlender, R ;
Schutz, C ;
Moller, HJ ;
Soyka, M .
PHARMACOPSYCHIATRY, 1997, 30 (03) :108-108
[6]  
Bruun T G, 1993, Ugeskr Laeger, V155, P2711
[7]  
BUZOSANCHEZ LG, 1996, AM J HEALTH-SYST PH, V53, P2638
[8]  
CARDINALE V, 1996, DRUG TOPICS REDBOOK, P98
[9]   TOLERANCE AND WITHDRAWAL WITH ZOLPIDEM [J].
CAVALLARO, R ;
REGAZZETTI, MG ;
COVELLI, G ;
SMERALDI, E .
LANCET, 1993, 342 (8867) :374-375
[10]  
CLUYDTS RJ, 1993, ACTA THERAP, V19, P73